Soriot’s $3.5B Brilinta dream is dashed by yet another big trial flop for AstraZeneca
Four years ago, when Pascal Soriot stepped to the helm of the faltering AstraZeneca, he based his turnaround plan on a vow that the pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
